Dr Jane Grove's Outputs (40)

Transcriptomic and proteomic characterization of cell and protein biomarkers of checkpoint inhibitor-induced liver injury (2025)
Journal Article
Ji, C., Kumpf, S., Qian, J., Federspiel, J. D., Sheehan, M., Capunitan, D., Atallah, E., Astbury, S., Arat, S., Oziolor, E., Ocana, M. F., Ramaiah, S. K., Grove, J., Aithal, G. P., & Lanz, T. A. (2025). Transcriptomic and proteomic characterization of cell and protein biomarkers of checkpoint inhibitor-induced liver injury. Cancer Immunology, Immunotherapy, 74(6), Article 190. https://doi.org/10.1007/s00262-025-04033-z

Immune checkpoint inhibitors (ICI) targeting CTLA-4 and PD-1 have shown remarkable antitumor efficacy, but can also cause immune-related adverse events, including checkpoint inhibitor-induced liver injury (ChILI). This multi-omic study aimed to inves... Read More about Transcriptomic and proteomic characterization of cell and protein biomarkers of checkpoint inhibitor-induced liver injury.

The development of a food-group, tree classification method and its use in exploring dietary associations with Metabolic dysfunction-Associated Steatotic Liver Disease (MASLD) and other health-related outcomes in a UK Population (2025)
Journal Article
Alawadi, A. A., Vijay, A., Grove, J. I., Taylor, M. A., & Aithal, G. P. (2025). The development of a food-group, tree classification method and its use in exploring dietary associations with Metabolic dysfunction-Associated Steatotic Liver Disease (MASLD) and other health-related outcomes in a UK Population. Metabolism Open, 25, Article 100351. https://doi.org/10.1016/j.metop.2025.100351

Background
Metabolic dysfunction-Associated Steatotic Liver Disease (MASLD) affects up to one in five people in the UK, with persistent overeating and a sedentary lifestyle being significant risk factors. Exploring dietary patterns at a food level i... Read More about The development of a food-group, tree classification method and its use in exploring dietary associations with Metabolic dysfunction-Associated Steatotic Liver Disease (MASLD) and other health-related outcomes in a UK Population.

Next-generation sequencing of pancreatic cyst wall specimens obtained using micro-forceps for improving diagnostic accuracy (2023)
Journal Article
Astbury, S., Baskar, A., Grove, J. I., Kaye, P., Aravinthan, A. D., James, M., Clarke, C., Aithal, G. P., & Venkatachalapathy, S. V. (2023). Next-generation sequencing of pancreatic cyst wall specimens obtained using micro-forceps for improving diagnostic accuracy. Endoscopy International Open, 11(10), E983-E991. https://doi.org/10.1055/a-2163-8805

Background and study aims: Pancreatic cysts are common incidental findings, with an estimated prevalence of 13-15% in imaging done for other reasons. Diagnosis often relies on collection of cyst fluid, but tissue sampling using micro-forceps may allo... Read More about Next-generation sequencing of pancreatic cyst wall specimens obtained using micro-forceps for improving diagnostic accuracy.

Study design for development of novel safety biomarkers of drug-induced liver injury by the translational safety biomarker pipeline (TransBioLine) consortium: a study protocol for a nested case–control study (2023)
Journal Article
Grove, J. I., Stephens, C., Lucena, M. I., Andrade, R. J., Weber, S., Gerbes, A., Bjornsson, E. S., Stirnimann, G., Daly, A. K., Hackl, M., Khamina-Kotisch, K., Marin, J. J. G., Monte, M. J., Paciga, S. A., Lingaya, M., Forootan, S. S., Goldring, C. E. P., Poetz, O., Lombaard, R., Stege, A., …on behalf of the TransBioLine consortium. (2023). Study design for development of novel safety biomarkers of drug-induced liver injury by the translational safety biomarker pipeline (TransBioLine) consortium: a study protocol for a nested case–control study. Diagnostic and Prognostic Research, 7, Article 18. https://doi.org/10.1186/s41512-023-00155-z

A lack of biomarkers that detect drug-induced liver injury (DILI) accurately continues to hinder early- and late-stage drug development and remains a challenge in clinical practice. The Innovative Medicines Initiative’s TransBioLine consortium compri... Read More about Study design for development of novel safety biomarkers of drug-induced liver injury by the translational safety biomarker pipeline (TransBioLine) consortium: a study protocol for a nested case–control study.

Biomarkers of Type IV Collagen Turnover Reflect Disease Activity in Patients with Early-Stage Non-Alcoholic Fatty Liver (NAFL) (2023)
Journal Article
Lønsmann, I., Grove, J. I., Haider, A., Kaye, P., Karsdal, M. A., Leeming, D. J., & Aithal, G. P. (2023). Biomarkers of Type IV Collagen Turnover Reflect Disease Activity in Patients with Early-Stage Non-Alcoholic Fatty Liver (NAFL). Biology, 12(8), Article 1087. https://doi.org/10.3390/biology12081087

Background: Identification of progressive liver disease necessitates the finding of novel non-invasive methods to identify and monitor patients in need of early intervention. Investigating patients with early-liver injury may help identify unique bio... Read More about Biomarkers of Type IV Collagen Turnover Reflect Disease Activity in Patients with Early-Stage Non-Alcoholic Fatty Liver (NAFL).

Identification and characterisation of a rare MTTP variant underlying hereditary non-alcoholic fatty liver disease (2023)
Journal Article
Grove, J. I., Lo, P. C., Shrine, N., Barwell, J., Wain, L. V., Tobin, M. D., Salter, A. M., Borkar, A. N., Cuevas-Ocaña, S., Bennett, N., John, C., Ntalla, I., Jones, G. E., Neal, C. P., Thomas, M. G., Kuht, H., Gupta, P., Vemala, V. M., Grant, A., Adewoye, A. B., …Aithal, G. P. (2023). Identification and characterisation of a rare MTTP variant underlying hereditary non-alcoholic fatty liver disease. JHEP Reports, 5(8), Article 100764. https://doi.org/10.1016/j.jhepr.2023.100764

Background & Aims: Non-alcoholic fatty liver disease (NAFLD) is a complex trait with an estimated prevalence of 25% globally. We aimed to identify the genetic variant underlying a four-generation family with progressive NAFLD leading to cirrhosis, de... Read More about Identification and characterisation of a rare MTTP variant underlying hereditary non-alcoholic fatty liver disease.

PRO-C3 is a predictor of clinical outcomes in distinct cohorts of patients with advanced liver disease (2023)
Journal Article
Nielsen, M. J., Dolman, G. E., Harris, R., Frederiksen, P., Chalmers, J., Grove, J. I., Irving, W. L., Karsdal, M. A., Patel, K., Leeming, D. J., & Guha, I. N. (2023). PRO-C3 is a predictor of clinical outcomes in distinct cohorts of patients with advanced liver disease. JHEP Reports, 5(6), Article 100743. https://doi.org/10.1016/j.jhepr.2023.100743

Background & Aims: Fibroblast activity is a key feature of fibrosis progression and organ function loss, leading to liver-related complications and mortality. The fibrogenesis marker, PRO-C3, has been shown to have prognostic significance in relation... Read More about PRO-C3 is a predictor of clinical outcomes in distinct cohorts of patients with advanced liver disease.

Tandem mass tag-based quantitative proteomic profiling identifies candidate serum biomarkers of drug-induced liver injury in humans (2023)
Journal Article
Ravindra, K. C., Vaidya, V. S., Wang, Z., Federspiel, J. D., Virgen-Slane, R., Everley, R. A., Grove, J. I., Stephens, C., Ocana, M. F., Robles-Díaz, M., Isabel Lucena, M., Andrade, R. J., Atallah, E., Gerbes, A. L., Weber, S., Cortez-Pinto, H., Fowell, A. J., Hussaini, H., Bjornsson, E. S., Patel, J., …Ramaiah, S. K. (2023). Tandem mass tag-based quantitative proteomic profiling identifies candidate serum biomarkers of drug-induced liver injury in humans. Nature Communications, 14, Article 1215. https://doi.org/10.1038/s41467-023-36858-6

Diagnosis of drug-induced liver injury (DILI) and its distinction from other liver diseases are significant challenges in drug development and clinical practice. Here, we identify, confirm, and replicate the biomarker performance characteristics of c... Read More about Tandem mass tag-based quantitative proteomic profiling identifies candidate serum biomarkers of drug-induced liver injury in humans.

Next-generation sequencing of pancreatic cyst wall specimens obtained using Moray micro-forceps for improving diagnostic accuracy (2023)
Preprint / Working Paper
Astbury, S., Baskar, A., Grove, J. I., Kaye, P., Aravinthan, A. D., James, M. W., Clarke, C., Aithal, G. P., & Venkatachalapathy, S. V. Next-generation sequencing of pancreatic cyst wall specimens obtained using Moray micro-forceps for improving diagnostic accuracy

Background and study aims Pancreatic cysts are common incidental findings, with an estimated prevalence of 13-15% in imaging done for other reasons. It is difficult to identify cysts with malignant potential. Diagnosis often relies on collection of c... Read More about Next-generation sequencing of pancreatic cyst wall specimens obtained using Moray micro-forceps for improving diagnostic accuracy.

Plasma Sphingoid Base Profiles of Patients Diagnosed with Intrinsic or Idiosyncratic Drug-induced Liver Injury (2023)
Journal Article
Gai, Z., Samodelov, S. L., Alecu, I., Hornemann, T., Grove, J. I., Aithal, G. P., Visentin, M., & Kullak-Ublick, G. A. (2023). Plasma Sphingoid Base Profiles of Patients Diagnosed with Intrinsic or Idiosyncratic Drug-induced Liver Injury. International Journal of Molecular Sciences, 24(3), Article 3013. https://doi.org/10.3390/ijms24033013

Sphingolipids are exceptionally diverse, comprising hundreds of unique species. The bulk of circulating sphingolipids are synthesized in the liver, thereby plasma sphingolipid profiles represent reliable surrogates of hepatic sphingolipid metabolism... Read More about Plasma Sphingoid Base Profiles of Patients Diagnosed with Intrinsic or Idiosyncratic Drug-induced Liver Injury.

Risk of liver fibrosis associated with long-term methotrexate therapy may be overestimated (2023)
Journal Article
Atallah, E., Grove, J., Crooks, C., Burden-Teh, E., Abhishek, A., Moreea, S., Jordan, K., Ala, A., Hutchinson, D., Aspinall, R. J., Murphy, R., & Aithal, G. (2023). Risk of liver fibrosis associated with long-term methotrexate therapy may be overestimated. Journal of Hepatology, 78(5), 989-997. https://doi.org/10.1016/j.jhep.2022.12.034

Background & Aims
The risk of significant liver fibrosis from prolonged methotrexate (MTX) exposure has been estimated at around 5%, prompting intensive monitoring strategies. However, the evidence is derived from retrospective studies that under-re... Read More about Risk of liver fibrosis associated with long-term methotrexate therapy may be overestimated.

Risk of liver fibrosis associated with long-term methotrexate therapy may be overestimated (2023)
Journal Article
Atallah, E., Grove, J. I., Crooks, C., Burden-Teh, E., Abhishek, A., Moreea, S., Jordan, K. M., Ala, A., Hutchinson, D., Aspinall, R. J., Murphy, R., & Aithal, G. P. (2023). Risk of liver fibrosis associated with long-term methotrexate therapy may be overestimated. Journal of Hepatology, 78(5), 989-997. https://doi.org/10.1016/j.jhep.2022.12.034

Background & Aims: The risk of significant liver fibrosis from prolonged methotrexate (MTX) exposure has been estimated at around 5%, prompting intensive monitoring strategies. However, the evidence is derived from retrospective studies that under-re... Read More about Risk of liver fibrosis associated with long-term methotrexate therapy may be overestimated.

Identification of Reduced ERAP2 Expression and a Novel HLA Allele as Components of a Risk Score for Susceptibility to Liver Injury Due to Amoxicillin-Clavulanate (2022)
Journal Article
Nicoletti, P., Dellinger, A., Li, Y. J., Barnhart, H. X., Chalasani, N., Fontana, R. J., Odin, J. A., Serrano, J., Stolz, A., Etheridge, A. S., Innocenti, F., Govaere, O., Grove, J. I., Stephens, C., Aithal, G. P., Andrade, R. J., Bjornsson, E. S., Daly, A. K., Lucena, M. I., & Watkins, P. B. (2023). Identification of Reduced ERAP2 Expression and a Novel HLA Allele as Components of a Risk Score for Susceptibility to Liver Injury Due to Amoxicillin-Clavulanate. Gastroenterology, 164(3), 454-466. https://doi.org/10.1053/j.gastro.2022.11.036

Background & Aims: Drug-induced liver injury (DILI) due to amoxicillin–clavulanate (AC) has been associated with HLA-A∗02:01, HLA-DRB1∗15:01, and rs2476601, a missense variant in PTPN22. The aim of this study was to identify novel risk factors for AC... Read More about Identification of Reduced ERAP2 Expression and a Novel HLA Allele as Components of a Risk Score for Susceptibility to Liver Injury Due to Amoxicillin-Clavulanate.

A new framework for advancing in drug-induced liver injury research. The Prospective European DILI Registry (2022)
Journal Article
Björnsson, E. S., Stephens, C., Atallah, E., Alvarez-Alvarez, I., Robles-Diaz, M., Gerbes, A., Weber, S., Stirnimann, G., Kullak-Ublick, G., Cortez-Pinto, H., Grove, J. I., Lucena, M. I., Andrade, R. J., & Aithal, G. P. (2022). A new framework for advancing in drug-induced liver injury research. The Prospective European DILI Registry. Liver International, 43(1), 115-126. https://doi.org/10.1111/liv.15378

Background & Aims: No multi-national prospective study of drug-induced liver injury (DILI) has originated in Europe. The design of a prospective European DILI registry, clinical features and short-term outcomes of the cases and controls is reported.... Read More about A new framework for advancing in drug-induced liver injury research. The Prospective European DILI Registry.

Development of Food Group Tree-Based Analysis and Its Association with Non-Alcoholic Fatty Liver Disease (NAFLD) and Co-Morbidities in a South Indian Population: A Large Case-Control Study (2022)
Journal Article
Vijay, A., Al-Awadi, A., Chalmers, J., Balakumaran, L., Grove, J. I., Valdes, A. M., Taylor, M. A., Shenoy, K. T., & Aithal, G. P. (2022). Development of Food Group Tree-Based Analysis and Its Association with Non-Alcoholic Fatty Liver Disease (NAFLD) and Co-Morbidities in a South Indian Population: A Large Case-Control Study. Nutrients, 14(14), Article 2808. https://doi.org/10.3390/nu14142808

Background: Non-alcoholic fatty liver disease (NAFLD) is a global problem growing in parallel to the epidemics of obesity and diabetes, with South Asians being particularly susceptible. Nutrition and behaviour are important modifiers of the disease,... Read More about Development of Food Group Tree-Based Analysis and Its Association with Non-Alcoholic Fatty Liver Disease (NAFLD) and Co-Morbidities in a South Indian Population: A Large Case-Control Study.

Comprehensive Comparative Analysis of Standard Validated, Genetic, and Novel Biomarkers to Enhance Prognostic Risk-Stratification in Patients With Hepatitis C Virus Cirrhosis (2022)
Journal Article
Innes, H., Walker, A. J., Benselin, J., Grove, J. I., Pedergnana, V., Azim Ansari, M., Lin, S. K., McLauchlan, J., Hutchinson, S. J., Barnes, E., Irving, W. L., & Guha, I. N. (2022). Comprehensive Comparative Analysis of Standard Validated, Genetic, and Novel Biomarkers to Enhance Prognostic Risk-Stratification in Patients With Hepatitis C Virus Cirrhosis. Clinical and Translational Gastroenterology, 13(3), Article e00462. https://doi.org/10.14309/ctg.0000000000000462

INTRODUCTION: Risk-stratifying patients with hepatitis C virus (HCV) cirrhosis according to medium-term prognosis will inform clinical decision-making. It is unclear which biomarkers/models are optimal for this purpose. We quantified the discriminati... Read More about Comprehensive Comparative Analysis of Standard Validated, Genetic, and Novel Biomarkers to Enhance Prognostic Risk-Stratification in Patients With Hepatitis C Virus Cirrhosis.

Integrins as a drug target in liver fibrosis (2022)
Journal Article
Rahman, S. R., Roper, J. A., Grove, J. I., Aithal, G. P., Pun, K. T., & Bennett, A. J. (2022). Integrins as a drug target in liver fibrosis. Liver International, 42(3), 507-521. https://doi.org/10.1111/liv.15157

As the worldwide prevalence of chronic liver diseases is high and continuing to increase, there is an urgent need for treatment to prevent cirrhosis-related morbidity and mortality. Integrins are heterodimeric cell-surface proteins that are promising... Read More about Integrins as a drug target in liver fibrosis.

Chronic liver disease in homeless individuals and performance of non‐invasive liver fibrosis and injury markers: VALID study (2021)
Journal Article
Hashim, A., Bremner, S., Grove, J., Astbury, S., Mengozzi, M., O’Sullivan, M., Macken, L., Worthley, T., Katarey, D., Aithal, G., & Verma, S. (2022). Chronic liver disease in homeless individuals and performance of non‐invasive liver fibrosis and injury markers: VALID study. Liver International, 42(3), 628-639. https://doi.org/10.1111/liv.15122

Background/aims: Community-based assessment and management of chronic liver disease (CLD) in people who are homeless (PWAH) remains poorly described. We aimed to determine prevalence/predictors of chronic liver disease (CLD) in PWAH and assess perfor... Read More about Chronic liver disease in homeless individuals and performance of non‐invasive liver fibrosis and injury markers: VALID study.

Effects of an isoenergetic low Glycaemic Index (GI) diet on liver fat accumulation and gut microbiota composition in patients with non-alcoholic fatty liver disease (NAFLD): A study protocol of an efficacy mechanism evaluation (2021)
Journal Article
Al-Awadi, A., Grove, J., Taylor, M., Valdes, A., Vijay, A., Bawden, S., Gowland, P., & Aithal, G. (2021). Effects of an isoenergetic low Glycaemic Index (GI) diet on liver fat accumulation and gut microbiota composition in patients with non-alcoholic fatty liver disease (NAFLD): A study protocol of an efficacy mechanism evaluation. BMJ Open, 11(10), Article e045802. https://doi.org/10.1136/bmjopen-2020-045802

Introduction A Low Glycaemic Index (LGI) diet is a proposed lifestyle intervention in non-alcoholic fatty liver diseases (NAFLD) which is designed to reduce circulating blood glucose levels, hepatic glucose influx, insulin resistance and de novo lipo... Read More about Effects of an isoenergetic low Glycaemic Index (GI) diet on liver fat accumulation and gut microbiota composition in patients with non-alcoholic fatty liver disease (NAFLD): A study protocol of an efficacy mechanism evaluation.

Reliable computational quantification of liver fibrosis is compromised by inherent staining variation (2021)
Journal Article
Astbury, S., Grove, J. I., Dorward, D. A., Guha, I. N., Fallowfield, J. A., & Kendall, T. J. (2021). Reliable computational quantification of liver fibrosis is compromised by inherent staining variation. Journal of Pathology: Clinical Research, 7(5), 471-481. https://doi.org/10.1002/cjp2.227

Biopsy remains the gold standard measure for staging liver disease, both to inform prognosis and to assess the response to a given treatment. Semiquantitative scores such as the Ishak fibrosis score are used for evaluation. These scores are utilised... Read More about Reliable computational quantification of liver fibrosis is compromised by inherent staining variation.